Annals of Surgical Oncology

, Volume 19, Issue 6, pp 1723–1731 | Cite as

Hereditary Breast Cancer: Practical Pursuit for Clinical Translation

Risk Assessment and Genetic Testing for Hereditary Breast Cancer


The benefits of a skillful medical history and histologic confirmation of relevant pathology are potentially lifesaving. Appropriately directed DNA testing based on these initial steps provides an opportunity for clinical translation into a cancer prevention program targeted to family members. Unfortunately, cancer prevention strategies that are based on genetics are frequently overlooked or underestimated in the overall practical management of patients at high risk for breast cancer as well as integral cancers that constitute a hereditary breast cancer syndrome. DNA testing, particularly for BRCA1 and BRCA2 in hereditary breast–ovarian cancer syndrome and p53 in the Li-Fraumeni syndrome, and many other syndromes is commercially available for inclusion in a cancer control program and merits attention in this major public health problem. It is clear that the time and effort expended for a hereditary cancer syndrome diagnosis may significantly reduce both morbidity and mortality in breast cancer. We have found that genetic counselors can partner with the clinical physicians and make significant contributions to this labor-intensive effort.



This work was supported by revenue from Nebraska cigarette taxes awarded to Creighton University by the Nebraska Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the State of Nebraska or the Nebraska Department of Health and Human Services. H.L.’s work is partially funded through the Charles F. and Mary C. Heider Chair in Cancer Research, which he holds at Creighton University.


  1. 1.
    International Agency for Research on Cancer. Globocan 2008.
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  3. 3.
    Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2010;318:1108–13.CrossRefGoogle Scholar
  4. 4.
    Lin J, Gan CM, Zhang X, et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res. 2010;17:1304–18.CrossRefGoogle Scholar
  5. 5.
    Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2010;314:268–74.CrossRefGoogle Scholar
  6. 6.
    Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Easton DF, Pooley KA, Dunning AM, et al.; the SEARCH Collaborators. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS. Hereditary breast–ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol. 2003;21:740–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Guttmacher AE, Collins FS, Carmona RH. The family history—more important than ever. N Engl J Med. 2004;351:2333–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Lynch HT, Boland CR, Rodriguez-Bigas MA, Amos C, Lynch JF, Lynch PM. Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol. 2007;25:3534–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Lynch HT, Marcus JN, Lynch J, Snyder CL, Rubinstein WS. Breast cancer genetics: syndromes, genes, pathology, counseling, testing, and treatment. In: Bland KI, Copeland EM III, editors. The breast: comprehensive management of benign and malignant disorders. 4th ed. Philadelphia, PA: Saunders; 2009. p 371–415.Google Scholar
  12. 12.
    Watson P, Narod SA, Fodde R, et al. Carrier risk status changes resulting from mutation testing in hereditary nonpolyposis colorectal cancer and hereditary breast–ovarian cancer. J Hum Genet. 2003;40:591–6.Google Scholar
  13. 13.
    Lynch HT, Marcus JN, Watson P, Lynch J. Familial breast cancer, cancer family syndromes, and predisposition to breast neoplasms. In: Bland K, Copeland EM, editors. The breast. Philadelphia: Saunders; 1991. p. 262–91.Google Scholar
  14. 14.
    Marcus J, Watson P, Linder-Stephenson L, Conway T, Page D, Lynch H. The pathobiology of BRCA1-linked and -unlinked hereditary breast cancer (HBC) (abstract). Mod Pathol. 1994;7:18A.Google Scholar
  15. 15.
    Claus EB, Risch N, Thompson WD, et al. Relationship between breast histopathology and family history of breast cancer. Am J Epidemiol. 1990;131:961–72.PubMedGoogle Scholar
  16. 16.
    Marcus J, Page D, Watson P, Conway T, Lynch H. High mitotic grade in hereditary breast cancer (abstract). Lab Invest. 1988;56:61A.Google Scholar
  17. 17.
    Rosen PP, Lesser ML, Senie MA, Kinne DW. Epidemiology of breast carcinoma III: relationship of family history to tumor type. Cancer. 1982;50:171–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Erdreich LS, Asal NR, Hoge AF. Morphologic types of breast cancer: age, bilaterality, and family history. Southern Med J. 1980;73:28–32.PubMedCrossRefGoogle Scholar
  19. 19.
    LiVolsi VA, Kelsey JL, Fischer DB, Holford TR, Mostow ED, Goldenberg IS. Effect of age at first childbirth on risk of developing specific histologic subtype of breast cancer. Cancer. 1982;49:1937–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Stalsberg H, Thomas DB, Noonan EA. The WHO collaborative study of neoplasia and steroid contraceptives. Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. Cancer. 1989;44:399–409.Google Scholar
  21. 21.
    Lagios MD, Rose MR, Margolin FR. Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma. Am J Clin Pathol. 1980;73:25–30.PubMedGoogle Scholar
  22. 22.
    Mosimann S, Torhorst JKH, Weber W, Muller H. Histopathological aspects of familial breast cancer. In: Weber W, Laffer UT, Durig M, editors. Hereditary cancer and preventive surgery. Karger: Basel; 1990. p 1–7.Google Scholar
  23. 23.
    Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and family history of breast cancer. Cancer. 1993;71:147–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Glebov OK, McKenzie KE, White CA, Sukumar S. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res. 1994;54:3703–9.PubMedGoogle Scholar
  25. 25.
    Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J. 2010;16:48–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Drew Y, Plummer R. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol. 2010;22:67–71.PubMedCrossRefGoogle Scholar
  28. 28.
    O’Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol. 2009;27:18s (suppl; abstr 3).Google Scholar
  29. 29.
    Hall MJ, Reid JE, Burbridge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Mangold KA, Wang V, Weissman SM, Rubinstein WS, Kaul KL. Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences. J Mol Diagn. 2010;12:20–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379–88.PubMedCrossRefGoogle Scholar
  32. 32.
    Díez O, Osorio A, Durán M, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat. 2003;22:301–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Huusko P, Juo SH, Gillanders E, et al. Genome-wide scanning for linkage in Finnish breast cancer families. Eur J Hum Genet. 2004;12:98–104.PubMedCrossRefGoogle Scholar
  34. 34.
    Smith P, McGuffog L, Easton DF, et al. A genome wide linkage search for breast cancer susuceptibility genes. Genes Chromosomes Cancer. 2006;45:646–55.PubMedCrossRefGoogle Scholar
  35. 35.
    Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010;362:986–93.PubMedCrossRefGoogle Scholar
  36. 36.
    Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Rebbeck TR, Lynch HT, Neuhausen SL, et al., for The Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–22.PubMedCrossRefGoogle Scholar
  38. 38.
    Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–62.PubMedCrossRefGoogle Scholar
  39. 39.
    Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.PubMedCrossRefGoogle Scholar
  40. 40.
    Lynch HT. Family information service and hereditary cancer. Cancer. 2001;91:625–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Lynch HT, Snyder C, Lynch J, Ghate S, Thome S. Family information service (FIS) in a BRCA1 extended family (abstract). J Clin Oncol. 2006;24:55s.Google Scholar
  42. 42.
    MacDonald DJ, Blazer KR, Weitzel JN. Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw. 2010;8:615–24.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  1. 1.Department of Preventive Medicine and Public HealthCreighton University School of MedicineOmahaUSA

Personalised recommendations